Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2024

23-06-2023 | Lymphoma | RESEARCH ARTICLE

Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma

Authors: Xiaohong Liu, Dedong Cao, Hui Liu, XiaoKang Ke, Xin Liu, Ximing Xu

Published in: Clinical and Translational Oncology | Issue 1/2024

Login to get access

Abstract

Objective

Nasal or extranasal natural killer/T-cell lymphoma (NKTCL) is a very rare aggressive lymphoma, but it is increasingly diagnosed. To evaluate some specificity by comparative analysis between primary upper aerodigestive tract (UAT) and non-upper aerodigestive tract (NUAT)NKTCL.

Methods

A retrospective analysis was performed on NKTCL patients from January 2013 to November 2022 in our cancer center.

Results

The majority of the lesions were UAT-NKTCL 70 cases (92.1%), the primary NUAT occurred in 6 cases. Patients in the UAT group were mainly in the early stage and in the low and medium risk, while those in the NUAT group were late stage and in high risk (p = 0.000). The expressions of CD3 and TIA-1 in UAT group were higher than those in NUAT group (p = 0.031, p = 0.003), while CD7 was dominant in NUAT group (p = 0.009). For early stage NKTCL, multivariate analysis suggested that gender and PINK score were independent factors affecting PFS and OS (p < 0.05). The 3 year OS rate in initial CR group was 90.1% versus 46.4% in non-CR group (p = 0.000). In advanced stage, KI67% and bone marrow involvement were independent factors affecting OS (p = 0.022, p = 0.038).

Conclusion

It was difficult to distinguish between UAT and NUAT-NKTCL from histopathology. NUAT-NKTCL patients did have advanced stage and poor outcome. The prognostic value of PINK score and bone marrow involvement was proposed. We aimed to improve initial CR rates, as well as to find new predictive models to predict the whole population.
Literature
1.
go back to reference Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;22(6):77.CrossRef Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;22(6):77.CrossRef
2.
go back to reference Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59(4):1127–37.CrossRefPubMed Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59(4):1127–37.CrossRefPubMed
3.
go back to reference Yang Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3(1):83–91.CrossRefPubMed Yang Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3(1):83–91.CrossRefPubMed
4.
go back to reference Boros A, Michot JM, Hoang-Xuan K, Mazeron R. Place de la radiothérapie dans la prise en charge des lymphomes NK/T de type nasal et primitifs cérébraux [Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas]. Cancer Radiother. 2016;20(6–7):535–42.CrossRefPubMed Boros A, Michot JM, Hoang-Xuan K, Mazeron R. Place de la radiothérapie dans la prise en charge des lymphomes NK/T de type nasal et primitifs cérébraux [Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas]. Cancer Radiother. 2016;20(6–7):535–42.CrossRefPubMed
5.
go back to reference Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–600.CrossRefPubMed Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–600.CrossRefPubMed
6.
go back to reference Wu T, Yang Y, Zhu SY, Shi M, Su H, Wang Y, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018;2(18):2369–77.CrossRefPubMedPubMedCentral Wu T, Yang Y, Zhu SY, Shi M, Su H, Wang Y, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018;2(18):2369–77.CrossRefPubMedPubMedCentral
7.
go back to reference Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–6.CrossRefPubMed Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–6.CrossRefPubMed
8.
go back to reference Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–80.CrossRefPubMed Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–80.CrossRefPubMed
9.
go back to reference Liu ZL, Bi XW, Zhang XW, Lei DX, Liu PP, Yang H, et al. Characteristics, prognostic factors, and survival of patients with NK/T-Cell lymphoma of non-upper Aerodigestive Tract: A 17-year single-center experience. Cancer Res Treat. 2019;51(4):1557–67.CrossRefPubMedPubMedCentral Liu ZL, Bi XW, Zhang XW, Lei DX, Liu PP, Yang H, et al. Characteristics, prognostic factors, and survival of patients with NK/T-Cell lymphoma of non-upper Aerodigestive Tract: A 17-year single-center experience. Cancer Res Treat. 2019;51(4):1557–67.CrossRefPubMedPubMedCentral
10.
go back to reference Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29(7):1571–7.CrossRefPubMed Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29(7):1571–7.CrossRefPubMed
11.
go back to reference Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35(1):130–42.CrossRefPubMed Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35(1):130–42.CrossRefPubMed
12.
go back to reference Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.CrossRefPubMed Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.CrossRefPubMed
13.
go back to reference Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.PubMed Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.PubMed
14.
go back to reference Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–68.CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–68.CrossRefPubMedPubMedCentral
15.
go back to reference Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020;21(2):306–16.CrossRefPubMed Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020;21(2):306–16.CrossRefPubMed
16.
go back to reference Huang Y, Chen S, Wei R, Guo X, Yang X, Cao Q, et al. CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows Arch. 2020;477(6):873–83.CrossRefPubMed Huang Y, Chen S, Wei R, Guo X, Yang X, Cao Q, et al. CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows Arch. 2020;477(6):873–83.CrossRefPubMed
17.
go back to reference Deng XW, Wu JX, Wu T, Zhu SY, Shi M, Su H, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiother Oncol. 2018;129(1):3–9.CrossRefPubMed Deng XW, Wu JX, Wu T, Zhu SY, Shi M, Su H, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiother Oncol. 2018;129(1):3–9.CrossRefPubMed
18.
go back to reference Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018;29(1):256–63.CrossRefPubMed Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018;29(1):256–63.CrossRefPubMed
19.
go back to reference Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100(2):366–75.CrossRefPubMed Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100(2):366–75.CrossRefPubMed
20.
go back to reference Qi F, Zhou W, Xie Y, Sun Y, Wu M, Chai Y, et al. Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation. Aging (Albany NY). 2022;14(21):8729–44.CrossRefPubMed Qi F, Zhou W, Xie Y, Sun Y, Wu M, Chai Y, et al. Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation. Aging (Albany NY). 2022;14(21):8729–44.CrossRefPubMed
21.
go back to reference Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, et al. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018;109(6):2056–62.CrossRefPubMedPubMedCentral Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, et al. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018;109(6):2056–62.CrossRefPubMedPubMedCentral
22.
go back to reference Yang Y, Wang Y, Liu X, He X, Zhang LL, Wu G, et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2021;35(6):1671–82.CrossRefPubMed Yang Y, Wang Y, Liu X, He X, Zhang LL, Wu G, et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2021;35(6):1671–82.CrossRefPubMed
23.
go back to reference Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Lymphoma subcommittee of the Korean cancer study group clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type a national survey of the Korean cancer study group. Ann Oncol. 2008;19(8):1477–84.CrossRefPubMed Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Lymphoma subcommittee of the Korean cancer study group clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type a national survey of the Korean cancer study group. Ann Oncol. 2008;19(8):1477–84.CrossRefPubMed
24.
go back to reference Alonso-Álvarez S, Alcoceba M, García-Álvarez M, Blanco O, Rodríguez M, Baile M, et al. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large B-cell lymphoma. Cancers (Basel). 2020;12(2):474.CrossRefPubMed Alonso-Álvarez S, Alcoceba M, García-Álvarez M, Blanco O, Rodríguez M, Baile M, et al. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large B-cell lymphoma. Cancers (Basel). 2020;12(2):474.CrossRefPubMed
25.
go back to reference He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;5(14):153.CrossRef He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;5(14):153.CrossRef
26.
go back to reference Wang JH, Wang H, Wang YJ, Xia ZJ, Huang HQ, Jiang WQ, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget. 2016;7(23):35412–22.CrossRefPubMedPubMedCentral Wang JH, Wang H, Wang YJ, Xia ZJ, Huang HQ, Jiang WQ, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget. 2016;7(23):35412–22.CrossRefPubMedPubMedCentral
27.
go back to reference Cai J, Liu P, Huang H, Li Y, Ma S, Zhou H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020;5(1):289.CrossRefPubMedPubMedCentral Cai J, Liu P, Huang H, Li Y, Ma S, Zhou H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020;5(1):289.CrossRefPubMedPubMedCentral
28.
go back to reference Du L, Zhang L, Li L, Li X, Yan J, Wang X, et al. Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for relapsed/refractory natural killer/T-Cell lymphoma: a report of three cases. Onco Targets Ther. 2020;27(13):7189–97.CrossRef Du L, Zhang L, Li L, Li X, Yan J, Wang X, et al. Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for relapsed/refractory natural killer/T-Cell lymphoma: a report of three cases. Onco Targets Ther. 2020;27(13):7189–97.CrossRef
29.
go back to reference Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–64.CrossRefPubMed Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–64.CrossRefPubMed
30.
Metadata
Title
Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma
Authors
Xiaohong Liu
Dedong Cao
Hui Liu
XiaoKang Ke
Xin Liu
Ximing Xu
Publication date
23-06-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03238-x

Other articles of this Issue 1/2024

Clinical and Translational Oncology 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine